Zai Lab Ltd (HK:9688)
:9688
Want to see HK:9688 full AI Analyst Report?
9688 Stock Chart & Stats
HK$18.27
-HK$0.02(-0.10%)
At close: 4:00 PM EST
HK$18.27
-HK$0.02(-0.10%)
Day’s Range― - ―
52-Week RangeHK$12.31 - HK$32.35
Previous CloseN/A
Volume1.30M
Average Volume (3M)10.12M
Market Cap
HK$16.25B
Enterprise ValueHK$1.43B
Total Cash (Recent Filing)HK$761.63M
Total Debt (Recent Filing)HK$232.00M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 10, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding1,134,128,000
10 Day Avg. Volume10,854,931
30 Day Avg. Volume10,116,373
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.68
Price to Sales (P/S)4.17
P/FCF Ratio-12.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$28.49Price Target Upside55.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.62
Revenue Forecast (FY)HK$3.55B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 58–66% indicate the business can retain a large portion of revenue after direct costs, supporting scalable profitability as commercial volumes rise. High product-level margins give flexibility to fund R&D and commercial expansion even amid top-line volatility.
Collaborative Licensing ModelA business model combining in-house R&D with licensing and partner collaborations diversifies revenue sources and shifts development risk. Upfronts, milestones and royalties create non-linear, contract-backed cash inflows and strategic access to global commercialization know-how over the medium term.
Regulatory Progress For Lead ADCEMA orphan designation is a structural regulatory milestone that can enable development incentives, potential market exclusivity and regulatory support in Europe. This formal recognition strengthens the commercial and development prospects of a novel DLL3-targeting ADC in a high-unmet-need niche.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the company relies on external financing to sustain operations and trials. That ongoing burn increases dilution or debt risk, constrains strategic optionality, and limits the capacity to self-fund late-stage programs over the coming months.
Sharp Recent Revenue ContractionA pronounced TTM revenue decline undermines cash predictability and makes it harder to leverage existing high gross margins into operating leverage. Revenue volatility raises execution risk for commercialization plans and complicates forecasting for funding and milestone timing over the next several quarters.
Rising Leverage & Negative ROELeverage increased versus prior years and equity has been eroded while returns on equity remain deeply negative. This signals capital is being consumed, elevating financing risk and reducing headroom for growth without further equity issuance or higher debt, pressuring long-term shareholder value.
Zai Lab Ltd News
9688 FAQ
What was Zai Lab Ltd’s price range in the past 12 months?
Zai Lab Ltd lowest stock price was HK$12.31 and its highest was HK$32.35 in the past 12 months.
What is Zai Lab Ltd’s market cap?
Zai Lab Ltd’s market cap is HK$16.25B.
When is Zai Lab Ltd’s upcoming earnings report date?
Zai Lab Ltd’s upcoming earnings report date is Aug 10, 2026 which is in 50 days.
How were Zai Lab Ltd’s earnings last quarter?
Zai Lab Ltd released its earnings results on May 07, 2026. The company reported -HK$0.36 earnings per share for the quarter, beating the consensus estimate of -HK$0.416 by HK$0.056.
Is Zai Lab Ltd overvalued?
According to Wall Street analysts Zai Lab Ltd’s price is currently Undervalued.
Does Zai Lab Ltd pay dividends?
Zai Lab Ltd does not currently pay dividends.
What is Zai Lab Ltd’s EPS estimate?
Zai Lab Ltd’s EPS estimate is -0.53.
How many shares outstanding does Zai Lab Ltd have?
Zai Lab Ltd has 1,134,128,000 shares outstanding.
What happened to Zai Lab Ltd’s price movement after its last earnings report?
Zai Lab Ltd reported an EPS of -HK$0.36 in its last earnings report, beating expectations of -HK$0.416. Following the earnings report the stock price went up 0.124%.
Which hedge fund is a major shareholder of Zai Lab Ltd?
Currently, no hedge funds are holding shares in HK:9688
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zai Lab Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$28.49 (55.91% Upside)
HK$28.49 (55.91% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-24.29%
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
Zai Lab Ltd
Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, and neurological conditions, primarily serving patients in Mainland China and Hong Kong. The company's portfolio of commercialized products includes Zejula, an oral, once-daily poly polymerase 1/2 inhibitor; Optune, a non-invasive device employing tumor treating fields; NUZYRA for addressing acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Zai Lab also maintains a robust pipeline of investigational therapies. This pipeline features numerous oncology assets such as Odronextamab for various lymphomas, Repotrectinib—a tyrosine kinase inhibitor targeting ROS1 and TRK fusions, Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated solid tumors, and Bemarituzumab for gastric and gastroesophageal junction cancers. Other notable pipeline candidates include CLN-081 for specific non-small cell lung cancers, multi-targeted kinase inhibitors like Elzovantinib, several monoclonal antibodies (e.g., Tebotelimab, Retifanlimab, ZL-1201), and immune modulators such as Efgartigimod for reducing disease-causing IgG antibodies and ZL-1102 targeting IL-17A. Additionally, the company is advancing therapies like KarXT for psychiatric and neurological disorders, novel EGFR inhibitors (ZL-2313, ZL-2314), a CDC7 kinase inhibitor (ZL-2309), and Sulbactam/durlobactam for serious Acinetobacter infections, showcasing its commitment to a broad range of therapeutic innovations.
9688 Stock 12 Month Forecast
Average Price Target
HK$28.49
▲(55.91% Upside)
Technical Analysis
InnoCare Pharma Ltd.
―
Everest Medicines Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---